Best practice in precision medicine for prostate cancer
Dr Piazza speaks with ecancer at EHA 23 about the expression and interaction of SETBP1 in driving myeloid leukaemia.
He details the network of expression, degradation and stabilisation of SETBP1 and BTRCP, which ultimately confirm that SETBP1 binds to genomic DNA and drives epigenetic mutations.
Best practice in precision medicine for prostate cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
EAU 2024: Bladder cancer latest
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia